About Alcresta therapeutics
Alcresta Therapeutics: Revolutionizing Enteral Nutrition with Enzyme Products
Alcresta Therapeutics is a leading biopharmaceutical company that specializes in developing innovative enzyme-based products for enteral nutrition. The company's mission is to improve the lives of patients who require tube feeding by providing them with safe, effective, and easy-to-use nutritional solutions.
Founded in 2008, Alcresta Therapeutics has quickly established itself as a pioneer in the field of enteral nutrition. The company's flagship product, Relizorb®, is a first-of-its-kind digestive enzyme cartridge that helps break down fats in tube feeding formulas. This breakthrough technology has been shown to significantly improve nutrient absorption and reduce gastrointestinal complications associated with tube feeding.
In addition to Relizorb®, Alcresta Therapeutics offers a range of other enzyme-based products designed to meet the unique nutritional needs of patients who require enteral feeding. These products include:
• Alkindi® Sprinkle – A sprinkle formulation of hydrocortisone for children with adrenal insufficiency who have difficulty swallowing tablets or capsules.
• Luminal® – An enzyme supplement that helps break down lactose in milk-based formulas for individuals with lactose intolerance.
• PERTZYE® – A pancreatic enzyme replacement therapy (PERT) used to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions.
All of these products are backed by extensive clinical research and have been shown to be safe and effective for use in patients requiring enteral nutrition.
One of the key advantages of Alcresta Therapeutics' products is their ease-of-use. Unlike traditional PERTs which require multiple capsules per meal, Relizorb® can be easily attached directly onto any standard enteral feeding set without any additional steps required. This makes it an ideal solution for healthcare providers looking to simplify their workflow while improving patient outcomes.
Another advantage is the cost-effectiveness of these products compared to traditional PERTs which can be expensive due to high dosing requirements. By using enzymes more efficiently through its proprietary technology platform, Alcresta Therapeutics' products offer significant cost savings while delivering superior clinical outcomes.
Overall, Alcresta Therapeutics represents an exciting new frontier in the field of enteral nutrition. With its innovative enzyme-based solutions and commitment to improving patient outcomes, this company is poised for continued growth and success as it continues its mission towards revolutionizing how we approach nutritional support for those who need it most.